tbuckley/cabot-search huggingface dataset:
Abstract 19360: Difference of Plaque Morphology on Coronary Spasm Type Evaluated by Coronary Angioscopy Compared With OCT
Authors: Daisuke Kitano, Tadateru Takayama, Mitsumasa Sudo, Takafumi Hiro, Atsushi Hirayama
Journal: Circulation (2017)

Introduction: Specific intracoronary findings on coronary vasospasm (CS) using several intracoronary imaging modalities have been reported. It is also documented that the characteristics are differ...
An Elderly Man With Periorbital Swelling and Sinus Congestion
Authors: Peter Glynn, Arvind Nishtala
Journal: JAMA Cardiology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
SAT0252 AN EVALUATION OF THREE DIFFERENT METHODS TO EVALUATE SKIN IMPAIRMENT IN SYSTEMIC SCLEROSIS PATIENTS
Authors: Barbara Ruaro, Vanessa Smith, Sabrina Paolino, Carmen Pizzorni, Stefano Soldano, Andrea Casabella, Massimo Patanè, Elisa Alessandri, Alberto Sulli, Maurizio Cutolo
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> One of the characteristics of systemic sclerosis (SSc) is an increase in dermal thickness (DT) (1-3). Although the standard method to evaluate the extent of skin involvement is the modified Rodnan skin score (mRSS) (3,4), high frequency ultrasounds (US) and the plicometer skin test (Plicometry) (5-8) are now being used in SSc patients. <h3>Objectives</h3> The aim of this study was to determine any correlations between mRSS, US and Plicometry during the evaluation of skin impairment in SSc patients. <h3>Methods</h3> A total of 63 SSc patients (mean age 64±13SD years, mean SSc duration 7±6 years) and 63 healthy subjects (HS) (mean age 64±12SD years) were enrolled. The three methods (mRSS, US and Plicometry) were used to evaluate skin impairment in the seventeen areas of the skin usually evaluated by mRSS (face, fingers, dorsum of hands, forearms, arms, chest, abdomen, thighs, legs and feet) and the total score was calculated, as previously reported (1,3,4,8). Intra-rater reliability of the three techniques was assessed by having the same rater performing 2 consecutive measurements at each skin site. Statistical evaluation was performed by non-parametric tests. <h3>Results</h3> A significant positive correlation was observed between the three methods used to evaluate DT in the SSc patients (mRSS vs US r=0.64, p&lt;0.0001; mRSS vs Plicometry r=0.97, p&lt;0.0001; US vs Plicometry r=0.55, p&lt;0.0001). Conversely, there was no correlation between these parameters in the CNT group (p&gt;0.05). The intraclass correlation coefficients for mRSS was 0.95, 0.97 for US and 0.96 for Plicometry. Data collection for mRSS took almost 10 minutes, 15 minutes for Plicometry and 20 minutes for US. <h3>Conclusion</h3> This study demonstrates a significant relationship between mRSS, US and Plicometry in the DT evaluation of SSc patients. The SSc patients had statistically significantly higher values than HS when the 3 techniques were used to evaluate the seventeen skin areas. <h3>References</h3> [1] Cutolo M, et al. Best Pract Res Clin Rheumatol. 2016;30:670-687. [2] Ruaro B, et al. Arthritis Rheumatol 2015; 67 (suppl 10). [3] Clements P, et al. J Rheumatol 1995;22:1281-5. [4] CzirjákL, et al. Ann Rheum Dis. 2007; 66: 966-9. [5] Hesselstrand R, et al. Rheumatology 2008;47:84-7. [6] Kaloudi O, et al. Ann Rheum Dis. 2010;69:1140-3. [7] Ruaro B, et al. Microvasc Res. 2018;115:28-33. [8] Parodi MN, et al. Br J Rheumatol. 1997;36:244-50. <h3>Disclosure of Interests</h3> None declared
THU0162 WHICH PERSISTENCE OF METHOTREXATE AFTER INITIATION OF THE 1ST BDMARD IN RHEUMATOID ARTHRITIS? THE RETRO-RIC2 STUDY
Authors: Guy Baudens, Tonione Adrien, Jean-Hugues Salmon, Jean-Guillaume Letarouilly, Elena Zinovieva, Hélène Herman-Demars, Elisabeth Gervais, Rene-Marc Flipo
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> ACR and EULAR guidelines recommend to prescribe bDMARDs and particularly TNFi in combination with methotrexate (MTX). However, the MTX observence in RA is poor, mainly due to side effect and some bDMARDs (IL6 receptor antagonist) are almost as effective in monotherapy. Objectives: to evaluate MTX use (dosage, route of administration…) in RA after initiation of the first bDMARD. <h3>Methods</h3> RETRO-RIC2 is a multicentric retrospective study. Were included all patients with RA under MTX therapy at the initiation of the 1<sup>st</sup> bDMARD from October 2008 to September 2016. The main criteria is the persistence of MTX after 1 and 2 years. <h3>Results</h3> 409 patients were included : mean-age = 58.9 years, female 69%, RF positive 76% and ACPA positive 83%, mean RA duration = 13.14y and mean DAS28-ES=4.48. The mean duration of previous MTX therapy = 32 months (mean dose = 16.2mg/w). At the inclusion MTX was administrated by oral route in 52% and subcutaneous in 48%. The first bDMARD was a TNF inhibitor in 70% At inclusion, 1.2% of the patients switch from oral route MTX for subcutaneous; inversely in only 0.2% the SC route was switched for oral administration. The results are presented in table 1 and Figure 1. V-1 = last previous visit before inclusion <h3>Conclusion</h3> In almost all patients MTX dose and route of administration are unchanged at the initiation of the first bDMARD in RA. With a 2 years follow up 49.9% of MTX dose were reduced and MTX was stopped in 2.9%. At 2 years MTX route of administration is oral for 64% of the patients and s/c for 36%. <h3>Acknowledgement</h3> None <h3>Disclosure of Interests</h3> Guy Baudens Grant/research support from: Financial Grant from NordicPharma, Consultant for: Roche SAS, TONIONE Adrien Grant/research support from: Grant from NordicPharma, Jean-Hugues Salmon Speakers bureau: Janssen Novartis, Jean-Guillaume Letarouilly: None declared, Elena Zinovieva Employee of: Nordic Pharma, Hélène Herman-Demars Employee of: Nordic Pharma, Elisabeth Gervais Grant/research support from: Roche, Pfizer, Consultant for: Bristol-Myers Squibb, UCB, Rene-Marc Flipo Consultant for: Advisory board: Bristol-Myers Squibb
Neutralization of CXCL12 attenuates established pulmonary hypertension in rats
Authors: Jennifer Bordenave, Raphaël Thuillet, Ly Tu, Carole Phan, Amélie Cumont, Claire Marsol, Alice Huertas, Laurent Savale, Marcel Hibert, Jean-Luc Galzi, Dominique Bonnet, Marc Humbert, Nelly Frossard, Christophe Guignabert
Journal: Cardiovascular Research (2019)

Abstract Aims The progressive accumulation of cells in pulmonary vascular walls is a key pathological feature of pulmonary arterial hypertension (PAH) that results in narrowing of the vessel lumen, but treatments targeting this mechanism are lacking. The C-X-C motif chemokine 12 (CXCL12) appears to be crucial in these processes. We investigated the activity of two CXCL12 neutraligands on experimental pulmonary hypertension (PH), using two complementary animal models. Methods and results Male Wistar rats were injected with monocrotaline (MCT) or were subjected to SU5416 followed by 3-week hypoxia to induce severe PH. After PH establishment, assessed by pulsed-wave Doppler echocardiography, MCT-injected or SU5416 plus chronic hypoxia (SuHx) rats were randomized to receive CXCL12 neutraligands chalcone 4 or LIT-927 (100 mg/kg/day), the C-X-C motif chemokine receptor 4 (CXCR4) antagonist AMD3100 (5 mg/kg/day), or vehicle, for 2 or 3 weeks, respectively. At the end of these treatment periods, echocardiographic and haemodynamic measurements were performed and tissue samples were collected for protein expression and histological analysis. Daily treatment of MCT-injected or SuHx rats with established PH with chalcone 4 or LIT-927 partially reversed established PH, reducing total pulmonary vascular resistance, and remodelling of pulmonary arterioles. Consistent with these observations, we found that neutralization of CXCL12 attenuates right ventricular hypertrophy, pulmonary vascular remodelling, and decreases pulmonary artery smooth muscle cell (PA-SMC) proliferation in lungs of MCT-injected rats and SuHx rats. Importantly, CXCL12 neutralization with either chalcone 4 or LIT-927 inhibited the migration of PA-SMCs and pericytes in vitro with a better efficacy than AMD3100. Finally, we found that CXCL12 neutralization decreases vascular pericyte coverage and macrophage infiltration in lungs of both MCT-injected and SuHx rats. Conclusion We report here a greater beneficial effect of CXCL12 neutralization vs. the conventional CXCR4 blockade with AMD3100 in the MCT and SuHx rat models of severe PH, supporting a role for CXCL12 in the progression of vascular complications in PH and opening to new therapeutic options.
AB0734B BONY BRIDGE ON FACET JOINT OR LATERAL SIDE OF LUMBAR VERTEBRA IS MORE FREQUENT AND CORRELATED WITH LUMBAR FLEXION FUNCTION THAN THAT ON ANTERIOR SIDE OF LUMBAR VERTEBRA IN ANKYLOSING SPONDYLITIS; ANALYSIS OF ANKYLOSIS REGISTRY OF AXIAL SPONDYLOARTHRITIS (ANKAS)
Authors: So Yun Lee, Seong Jong Yun, Ran Song, Sang-Hoon Lee
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> Ankylosing spondylitis (AS) is a form of chronic inflammatory arthritis characterized by sacroiliitis and a marked propensity for sacroiliac joint and spinal fusion. The modified Stoke ankylosing Spondylitis Spinal Score (mSASSS) has been used when measuring radiographic progression in aS, which only measures bony changes of anterior side in vertebral body (AV). Variation of this score is too small to assess radiographic progression in aS. Some patients have syndesmophytes on lateral side in vertebral body (LV) or ankylosis in facet joints (FJ). <h3>Objectives</h3> We planned this study to know which side of lumbar vertebra ankylosis more frequently develops in and is more correlated with lumbar flexion function. <h3>Methods</h3> We analyzed aNKylosis registry of axial Spondyloarthritis (ANKAS). In this cohort, the patients with aS are examined by anteroposterior and lateral view of X-ray every 2 years and low dose whole spine computed tomography (CT) every 5 years to determine radiographic progression. We analyzed the location of near total or total bone bridge at each level of lumbar spine by X-ray and CT in 518 patients with aS. <h3>Results</h3> Male was 78% and mean age was 38.8 ± 2.8. Ankylosis or bony bridge in sacroiliac joint (SIJ), FJ, LV and aV was respectively 55.2%, 22.8%, 21.6% and 13.1%. T12L1 was the most frequent level of ankylosis in FJ (31.7%) and LV (30.3%). For FJ and LV, there was a tendency that upper levels of spine have more ankylosis, but not in aV. The patients who didn't have SIJ ankylosis also have a tendency of not having any bony bridge in lumbar spine (negative predictive value: 92.24%, OR 28.1, 95% CI:16.3-48.4, p=0.000). We analyzed the correlation between the flexion score of Bath aS Metrology index (BASMI) 10 and the site of ankylosis. FJ ankylosis showed the strongest correlation with lumbar flexion range (R<sup>2</sup>=0.456, p=0.000), but bony bridge of LV and aV showed weak correlation with that (respectively, R<sup>2</sup>=0.288, R<sup>2</sup>=0.155, p=0.000). We analyzed the correlation between ankylosis of FJ and bony bridge of aV or LV respectively. Ankylosis of FJ and bony bridge of LV showed a stronger correlation (R<sup>2</sup>=0.712, p=0.000) than that of aV (R<sup>2</sup>=0.515, p=0.000) <h3>Conclusion</h3> Bony bridge in LV is not only more developed and correlated with ankylosis in FJ, but also more correlated with limitation of anterior lumbar flexion than that in aV. We suggest bony changes of LV should be also included in radiographic score system for more sensitive detection of radiographic progression in aS. <h3>Disclosure of interests</h3> None declared
Mutation profling in patients with carcinoma of unknown primary using the Sequenom MassARRAY system.
Authors: Katherine Stemke Hale, Huamin Wang, Siddharth Karanth, Martin N. Raber, Heather R. Carlson, Renato Lenzi, James L. Abbruzzese, Gordon B. Mills, Gauri R. Varadhachary
Journal: Journal of Clinical Oncology (2012)

4131 Background: CUP management may be viewed as an epitome of personalised medicine as we apply our understanding of biological markers to this heterogeneous disease. There is a significant interest in evaluating actionable mutations in various signaling pathways, receptors and downstream effectors in CUP that may help us understand its biology and serve as the basis for unique targeted therapeutic approaches. Sequenom (SQM) Massarray platform enables rapid mutation profiling in solid tumors which we applied to CUP. Methods: 83 CUP samples were sent for DNA mass array analysis. Sequenom was run on 60 samples; 23 samples lacked sufficient quantity or quality of DNA. Data on clinicopathological features was collected. Results: Of the 60 patient samples run on SQM, 16 patients had changes including 11 mutations and 6 polymorphisms . The 6 polymorphisms were in MET . The mutations reported were :RAS (7; 6 KRAS, 1 NRAS), IDH1 (2), PI3K (1) and MET (1). Atleast 50% of the tumors were poorly differentiated. Interestingly, the 2 patients with IDH1 mutations presented with osseous predominant metastatic disease. Of the 6 patients with KRAS mutations, 4 presented with a gastrointestinal profile ( CDX2+ or CK20+) on IHC; in all 4, the DNA sequencing analysis results matched the sequenom results. Conclusions: The (all-comers) overall mutation rate in a heterogenous CUP population is low (11/60, 18%). No "new" low frequency mutations were found using the current panel (Table). Rare and potentially targetable mutations may be identified with a larger panel. Focusing on CUP subsets using this approach may also provide a higher mutational yield. [Table: see text]
Where Sin3a Meets STAT3: Balancing STAT3-Mediated Transcriptional Activation and Repression
Authors: Emanuele Monteleone, Valeria Poli
Journal: Cancer Research (2019)

STAT3 can mediate epigenetic silencing of tumor suppressor genes (TSG). However, little is known about the molecular mechanisms involved, except that this action is mediated by DNA methylation and requires STAT3 acetylation. In this issue of Cancer Research, Gambi and colleagues confirm that oncogene-driven constitutive STAT3 acetylation is responsible for TSG silencing. Furthermore, they show that the Sin3a transcriptional repressor complex is an obligatory partner of STAT3 on the promoters of the repressed genes, shedding light on the mechanisms involved in STAT3-mediated transcriptional repression, and more importantly, identifying that the STAT3-Sin3a axis is a potential selective therapeutic target in STAT3-dependent tumors.See related article by Gambi et al., p. 3076.
Circular RNA circSLC8A1 acts as a sponge of miR-130b/miR-494 in suppressing bladder cancer progression via regulating PTEN
Authors: Qun Lu, Tianyao Liu, Huijin Feng, Rong Yang, Xiaozhi Zhao, Wei Chen, Bo Jiang, Haixiang Qin, Xu Guo, Minghui Liu, Limin Li, Hongqian Guo
Journal: Molecular Cancer (2019)

Circular RNAs (circRNAs) are a novel class of endogenous noncoding RNAs formed by a covalently closed loop, and increasing evidence has revealed that circRNAs play crucial functions in regulating gene expression. CircSLC8A1 is a circRNA generated from the SLC8A1 gene. Currently, the role and underlying molecular mechanisms of circSLC8A1 in bladder cancer remain unknown.The differentially expressed circRNAs were identified from RNA-sequencing data, and circSLC8A1 was determined as a new candidate circRNA. qRT-PCR was used to detect the expression of circRNAs, miRNAs and mRNAs in human tissues and cells. RNA pull-down assay and luciferase reporter assay were used to investigate the interactions between the specific circRNA, miRNA and mRNA. The effects of circSLC8A1 on bladder cancer cells were explored by transfecting with plasmids in vitro and in vivo. The expression of PTEN was detected by Western blot. The biological roles were measured by wound healing assay, transwell assay, and CCK-8 assay.In the present study, we found that circSLC8A1 was down-regulated in bladder cancer tissues and cell lines, and circSLC8A1 expression was associated with the pathological stage and histological grade of bladder cancer. Over-expression of circSLC8A1 inhibited cell migration, invasion and proliferation both in vitro and in vivo. Mechanistically, circSLC8A1 could directly interact with miR-130b/miR-494, and subsequently act as a miRNA sponge to regulate the expression of the miR-130b/miR-494 target gene PTEN and downstream signaling pathway, which suppressed the progression of bladder cancer.CircSLC8A1 acts as a tumor suppressor by a novel circSLC8A1/miR-130b, miR-494/PTEN axis, which may provide a potential biomarker and therapeutic target for the management of bladder cancer.
Grassroots organisations and the sustainable development goals: no one left behind?
Authors: Walter Flores, Jeannie Samuel
Journal: BMJ (2019)

Walter Flores and Jeannie Samuel argue that grassroots organisations are essential to ensure improvements in the health of marginalised populations A recent UN report indicates that local involvement with the sustainable development goals (SDGs) remains nascent at best in many countries.1 Grassroots organisations have a critical role in advancing progress towards the goals, especially at a subnational level.2 Nonetheless, these groups remain a largely untapped resource. Ensuring that "no one is left behind" is a commitment of the 2030 SDG plan. The SDGs seek not only to achieve national outcomes but also to reduce inequalities within countries. This is no small task. Often these inequalities have become normalised in state institutions. Provision of lower quality social services to geographically, economically, and socially marginalised populations is often seen.3 However, the SDGs provide only "very tentative suggestions for review structures at the national, regional, and global level." No mechanisms are provided for "independent civil society monitoring, data collection, and reporting."4 Emerging research on the involvement of grassroots organisations (box 1) in social accountability interventions suggests that these organisations could bridge that gap.567 Data produced by users of services and collected by grassroots organisations may be useful for monitoring the SDGs. This information could be used to contrast with, and complement, the data collected by official sources. Box 1 ### What are grassroots organisations? Grassroots organisations are groups of people pursuing common interests, largely on a volunteer and not-for-profit basis. Often such organisations are formed by activists in social movements. Many are closely linked to communities and local concerns. The term often refers to voluntary associations through which "disadvantaged people organise themselves to improve the social, cultural, and economic wellbeing of their families, communities, and societies."8 People have different conceptions of what constitutes the grassroots, but we apply the term to associations … RETURN TO TEXT
INTEGRATED PROFILING OF DNA METHYLATION AND MUTATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES
Authors: S. Morimoto, H. Makishima, Y. Nagata, C. Baer, N. Nadarajah, G. Nagae, Y. Nannya, Y. Miyazaki, K. Yoshida, T. Yoshizato, M. Nakagawa, R. Inagaki, J. Takeda, Y. Fujii, Y. Takeuchi, H. Ueno, Y. Shiraishi, K. Chiba, H. Tanaka, M. Sanada, S. Miyano, C. Haferlach, W. Kern, H. Aburatani, T. Haferlach, S. Ogawa
Journal: HemaSphere (2019)
Are there differences in risk factors, microbial aspects, and prognosis of cellulitis between compensated and decompensated hepatitis C virus-related cirrhosis?
Authors: Elham Ahmed Hassan, Abeer Sharaf El-Din Abdel Rehim, Mohamed Omar Abdel-Malek, Asmaa Omar Ahmed, Nourhan Mahmoud Abbas
Journal: Clinical and Molecular Hepatology (2019)

Cellulitis is a common infection in patients with liver cirrhosis. We aimed to compare risk factors, microbial aspects, and outcomes of cellulitis in compensated and decompensated hepatitis C virus (HCV)-related cirrhosis.Six hundred twenty consecutive HCV-related cirrhotic patients were evaluated for cellulitis. Demographic and clinical data were evaluated, along with blood and skin cultures. Severity of cirrhosis was assessed using Child-Pugh score. In-hospital mortality was assessed.Seventy-seven (12.4%) cirrhotic patients had cellulitis (25 with compensated and 52 with decompensated disease). Smoking and venous insufficiency were risk factors of cellulitis in compensated cirrhosis. Leg edema, ascites, hyperbilrubinemia and hypoalbuminemia were risk factors in decompensated cirrhosis. Gram-positive bacteria (Staphylococcus spp. and Streptococcus pyogenes) were the infective organisms in compensated patients, while gram negative bacteria (Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa) were the predominant organisms in decompensated cirrhosis. Fungi (Candida albicans and Aspergillus niger) were detected in 3 decompensated cases. In-hospital mortality in patients with cellulitis was 27.3%, approaching 100% in decompensated patients with gram-negative cellulitis. Prolonged hospitalization, higher model for end-stage liver disease (MELD)-Na score, septic shock, local complication, and recurrent cellulitis were predictors of mortality.Cellulitis in compensated cirrhosis is different from that of decompensated patients regarding microorganisms, pathogenesis, and prognosis. Cellulitis has a poor prognosis, with mortality rates approaching 100% in decompensated patients with gram-negative cellulitis. Stratifying patients according to severity of cirrhosis is important to identify the proper empirical antibiotic and to decide the proper means of care.